CTLA4 and liposarcoma: The most popular immunotargets include programmed cell death protein (PD)-1 and its ligand PD-L1 as well as cytotoxic T-lymphocyte-associated protein (CTLA)-4.204 Clinical trials are currently investigating the potential of monoclonal antibodies (mAB) against PD-L1 and CTLA-4 to treat DDLPS and pleiomorphic liposarcoma (NCT02500797 and NCT03114527).